Cargando…

PK/PD model‐informed dose selection for oncology phase I expansion: Case study based on PF‐06939999, a PRMT5 inhibitor

The optimal dose for targeted oncology therapeutics is often not the maximum tolerated dose. Pharmacokinetic/pharmacodynamic (PK/PD) modeling can be an effective tool to integrate clinical data to help identify the optimal dose. This case study shows the utility of population PK/PD modeling in selec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Cen, Liao, Kai H., Li, Meng, Wang, I‐Ming, Shaik, Naveed, Yin, Donghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681508/ https://www.ncbi.nlm.nih.gov/pubmed/36394153 http://dx.doi.org/10.1002/psp4.12882

Ejemplares similares

Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets
por: Zhou, Yu-Feng, et al.
Publicado: (2020)

Model‐Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
por: Sou, Tomás, et al.
Publicado: (2020)

Pharmacokinetics (PK), Pharmacodynamics (PD) and Integrated PK/PD Modeling of a Novel Long Acting FGF21 Clinical Candidate PF-05231023 in Diet-Induced Obese and Leptin-Deficient Obese Mice
por: Weng, Yan, et al.
Publicado: (2015)

The Role of PRMT5 in Immuno-Oncology
por: Abe, Yoshinori, et al.
Publicado: (2023)

PK/PD modeling supports the dose-escalation decision in VIKING
por: Lovern, M, et al.
Publicado: (2010)

PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing
por: Chen, Yewei, et al.
Publicado: (2020)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction
por: Ahmad, Ijaz, et al.
Publicado: (2016)

PK-PD Modeling and Optimal Dosing Regimen of Acetylkitasamycin against Streptococcus suis in Piglets
por: Huang, Anxiong, et al.
Publicado: (2022)

Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
por: Grant, Joshuaine, et al.
Publicado: (2023)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Integration of PK/PD for dose optimization of Cefquinome against Staphylococcus aureus causing septicemia in cattle
por: Ahmad, Ijaz, et al.
Publicado: (2015)

Corrigendum to “Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction”
por: Ahmad, Ijaz, et al.
Publicado: (2017)

Optimization of florfenicol dose against Piscirickettsia salmonis in Salmo salar through PK/PD studies
por: San Martín, Betty, et al.
Publicado: (2019)

Comment on “Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction”
por: Benini, Anna, et al.
Publicado: (2017)

Pharmacodynamic Evaluation and PK/PD-Based Dose Prediction of Tulathromycin: A Potential New Indication for Streptococcus suis Infection
por: Zhou, Yu-Feng, et al.
Publicado: (2017)

Protein kinase PfPK2 mediated signalling is critical for host erythrocyte invasion by malaria parasite
por: Rawat, Rahul Singh, et al.
Publicado: (2023)

PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK‐PD modeling from nonclinical to clinical development
por: Oggianu, Laura, et al.
Publicado: (2023)

Vertical Integration of Pharmacogenetics in Population PK/PD Modeling: A Novel Information Theoretic Method
por: Knights, J, et al.
Publicado: (2013)

Absolute Oral Bioavailability of Glasdegib (PF‐04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers
por: Shaik, Naveed, et al.
Publicado: (2019)

The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum
por: Zhang, Nan, et al.
Publicado: (2016)

The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2021)

Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats
por: Fernández-Varón, Emilio, et al.
Publicado: (2016)

Prmt5 is a regulator of muscle stem cell expansion in adult mice
por: Zhang, Ting, et al.
Publicado: (2015)

PK-PD correlation of anti-infective agents for dose adjustment in one severe burn child with sepsis
por: Campos, EV, et al.
Publicado: (2011)

Once Daily High Dose Tigecycline Is Optimal: Tigecycline PK/PD Parameters Predict Clinical Effectiveness
por: Baron, Jeffrey, et al.
Publicado: (2018)

Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
por: Shaik, Naveed, et al.
Publicado: (2018)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer
por: Lee, Tien‐Yi, et al.
Publicado: (2022)

The role of population PK–PD modelling in paediatric clinical research
por: De Cock, Roosmarijn F. W., et al.
Publicado: (2010)

PK/PD analysis of biapenem in patients undergoing continuous hemodiafiltration
por: Akashita, Gaku, et al.
Publicado: (2015)

PK-PD Analysis of Marbofloxacin against Streptococcus suis in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

The PK/PD Integration and Resistance of Tilmicosin against Mycoplasma hyopneumoniae
por: Huang, Zilong, et al.
Publicado: (2020)

S17.3 PK/PD in the treatment of hospital-acquired pneumonia
Publicado: (2005)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2019)

Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach
por: Maguigan, Kelly L., et al.
Publicado: (2021)

Dose Optimization of Vancomycin for Critically Ill Patients Undergoing CVVH: A Prospective Population PK/PD Analysis
por: Wang, Chuhui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vh65uu8784tecnrtlceb5i74m9